Aspire Biopharma Holdings, Inc.
ASBP
$8.87
-$0.38-4.11%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 162.32% | 122.87% | 302.78% | 433.39% | 459.34% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 130.82% | 127.10% | 331.60% | 552.17% | 561.72% |
| Operating Income | -127.68% | -125.67% | -331.08% | -551.86% | -561.72% |
| Income Before Tax | 41.55% | 30.89% | -1,770.33% | -3,215.38% | -3,924.61% |
| Income Tax Expenses | -- | -- | -- | -100.00% | 100.00% |
| Earnings from Continuing Operations | 41.55% | 30.89% | -1,768.91% | -3,207.38% | -3,920.54% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 41.55% | 30.89% | -1,768.91% | -3,207.38% | -3,920.54% |
| EBIT | -127.68% | -125.67% | -331.08% | -551.86% | -561.72% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 79.54% | 69.40% | -1,046.91% | -2,567.89% | -4,078.92% |
| Normalized Basic EPS | 12.88% | -52.03% | -245.77% | -640.18% | -877.22% |
| EPS Diluted | 79.54% | 69.40% | -1,046.91% | -2,567.89% | -4,078.92% |
| Normalized Diluted EPS | 12.88% | -52.03% | -245.77% | -640.18% | -877.22% |
| Average Basic Shares Outstanding | 1,012.97% | 222.37% | 116.52% | -99.97% | -99.97% |
| Average Diluted Shares Outstanding | 1,012.97% | 222.37% | 116.52% | -99.97% | -99.97% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |